ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma
Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point.
--------
7:02
--------
7:02
Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH
She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.
--------
15:36
--------
15:36
ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS
He describes how Rigel became focused on both on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.
--------
10:13
--------
10:13
ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients
Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026.
--------
7:12
--------
7:12
ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis
He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.